8 Red Days In A Row: Beam Therapeutics Stock Is Down 27%
A persistent slide in this gene-editing stock prompts a closer look at the numbers behind the negative momentum.
Beam Therapeutics (BEAM) Inc. develops precision genetic medicines for patients suffering from serious diseases in the United States. The market has put the stock on a sustained slide, with shares of BEAM moving lower for 8 consecutive trading days. This has resulted in a cumulative loss of 27.4% and erased about $1.1 billion from the company’s market value.
The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia.
BEAM Versus The S&P 500, Streak And Beyond
Here is how BEAM stock stacks up against the S&P 500 over the streak and the periods around it:
| Return Period | BEAM | S&P 500 |
|---|---|---|
| 1D | -3.0% | -1.0% |
| 8D (Current Streak) | -27.4% | -0.6% |
| 1M (21D) | -11.2% | -0.7% |
| 3M (63D) | -9.2% | 5.9% |
| YTD 2026 | -0.7% | 8.9% |
| 2025 | 11.8% | 16.4% |
| 2024 | -8.9% | 23.3% |
| 2023 | -30.4% | 24.2% |
The selling highlights a conflict between growth and profitability.
While Beam Therapeutics’ revenue grew 158.0% over the last twelve months, far outpacing the S&P 500 median of 7.5%, its operations show significant strain. The company’s operating margin is -226.6%, compared to an S&P 500 median of 18.4%. BEAM also has negative trailing earnings. The move appears specific to the company, as the S&P 500 returned -0.6% over the same period. Such streaks are not uncommon; currently, 37 S&P 500 stocks are on winning streaks of three days or more, while 38 are on losing streaks.
A streak is a signal to re-evaluate, not a command to act.
An extended move in either direction is primarily information. It signals that the market’s attention is focused on a stock, forcing a narrative into the open. For a disciplined investor, the key is not to follow the momentum but to use it as a prompt. The data here allows you to check the business fundamentals against the new, lower price and decide if the market’s recent judgment aligns with your own.
A slide like this always poses the same follow-up: which marked-down stocks are actually worth buying? Our Buy the Dip screen runs that test every day, flagging beaten-down names whose fundamentals still hold up.
Those watching the group rather than this one name have another route: a biotech ETF like XBI owns the whole group. It is still a concentrated bet on that one theme, though, which is exactly the gap the portfolio below closes.
Weakness In One Name Should Be Noise, Not News
For a diversified holder, a streak like this is a data point. For a concentrated one, it is a hole in the plan. The difference is never the stock; it is the portfolio built around it.
Building that portfolio is what the Trefis High Quality (HQ) Portfolio does: roughly 30 businesses with the cash generation and balance-sheet strength to absorb a bad month, selected and rebalanced by rules. It has a track record of outpacing a benchmark that combines all major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Make the next streak, in either direction, someone else’s drama.